SMMT News & Events

Summit Therapeutics announced overall survival, OS, results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit's partner Akeso, will be presented as part of the Plenary Session at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. The presentation is entitled "Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial." HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared to tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer, NSCLC, irrespective of PD-L1 expression. HARMONi-6 is a single region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusively generated, managed, and analyzed by Akeso. The trial's primary endpoint is progression-free survival, PFS, and OS is a key secondary endpoint.

Summit Therapeutics presented new results from the AK112-206 trial, a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were presented today at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. In this U.S.- and China-based Phase II cohort of treatment-naive patients with mCRC, patients receiving ivonescimab in combination with standard-of-care doublet chemotherapy mFOLFOX6 demonstrated an objective response rate of 70.8% across both arms in evaluable patients. This result is encouraging compared to historical performance of standard-of-care regimens combining bevacizumab with FOLFOX chemotherapy from prior studies.

Stocks closed higher on Friday amid strong earnings and cautious signs of progress toward ending the U.S. conflict with Iran. The Dow advanced to a record high, while the S&P 500 and the Nasdaq 100 posted their eighth week of gains ahead of the long holiday weekend.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Estee Lauderand Puigannounced that the parties haveregarding a potential business combinationImaxis exploring a sale, according toWorkdayreportedand reiterated its FY27 revenue guidanceZoom Communicationsprovided areport for Q1Deckers Outdoorreportedand provided its outlook for FY272. WALL STREET CALLS:JPMorganSweetgreenon ramping brand transformationViking Holdingsto Buy at Truist on strong demand trendsJefferiesGeneracon data center contract potentialSummit Therapeuticsto Neutral at H.C. WainwrightInspire Medicalto Underperform at BofA on coding overhang3. AROUND THE WEB:Nintendoaims to make about 20M Switch 2 consoles in the year through March, Bloomberg reportsMicrosoftagreed to pay $250M to settle investor litigation over its massive takeover Activision Blizzard, Bloomberg saysSony'sBungie plans to lay off a significant number of workers as it concludes active development on "Destiny 2," Bloomberg saysStarbucksshut down an AI program for automating inventory counts, nine months after deploying it, after it frequently miscounted and mislabeled items, Reuters saysSamsungis set to distribute about $26.6B to its 78,000 chip employees, or a $340,000 bonus to each, in early 2027 as part of a last-minute labor union deal, Bloomberg reports4. MOVERS:Pelotongained afterEnviriin the S&P 600Rocket Labsincreased after completing its ninthGileadwas higher after the FDA approved the company'sFutu Holdingsand UP Fintechfell in New York afterhas launched a broad crackdown on unauthorized cross-border investingImmunityBiodeclined after reportingand presenting preliminary results from a new health economic analysis on that ANKTIVA plus Bacillus Calmette-Guerin5. EARNINGS/GUIDANCE:BJ's Wholesaleand backed its guidance for FY26 after what CEO Bob Eddy called "a strong first quarter"Take-Two, with EPS missing consensusBooz Allenand provided guidance for FY27Ross Stores, with EPS and revenue beating consensusGlobal Ship Lease, with EPS lower year-over-yearINDEXES:The Dow rose 294.04, or 0.58%, to 50,579.70, the Nasdaq gained 50.87, or 0.19%, to 26,343.97, and the S&P 500 advanced 27.75, or 0.37%, to 7,473.47.